The "Defending Affordable Prescription Drug Costs Act" aims to prohibit discrimination against 340B covered entities and their contract pharmacies by health insurers, pharmacy benefit managers, and pharmaceutical manufacturers. The act specifically forbids these entities from establishing lower reimbursement rates for 340B drugs compared to non-340B drugs based solely on the drug's 340B status, imposing different fees or conditions based on 340B status, denying participation in pharmacy networks, and other discriminatory actions. It also restricts pharmaceutical manufacturers from denying, restricting, prohibiting, or interfering with the acquisition and dispensing of 340B drugs by contract pharmacies.

Additionally, the act mandates that each 340B covered entity participating in the federal 340B drug pricing program submit an annual report detailing their participation, including financial data such as the aggregated acquisition cost of drugs, payment amounts received, and the use of savings to benefit patients and the community. Violations of this act will be considered violations of chapter 13.1 of title 6 regarding unfair sales practices. The provisions of the act are designed to ensure compliance with federal regulations and will take effect on October 1, 2025.